The use of existing natriuretic agents for treating ascites associated with liver cirrhosis is problematic for the following reasons: hyponatremia is likely to occur; diuresis resistance or impaired renal function is induced by the activation of the renin–angiotensin–aldosterone system; and hypoalbuminemia-associated treatment resistance may occur. The gene discussed is REN; the disease is cirrhosis of liver.